These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)]. Buschulte K; Hoffmann-Vold AM; Dobrota RD; Höger P; Krause A; Kreuter M Z Rheumatol; 2021 Oct; 80(8):743-754. PubMed ID: 34505934 [TBL] [Abstract][Full Text] [Related]
44. Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?). Kreuter M; Wälscher J; Behr J Curr Opin Pulm Med; 2017 Sep; 23(5):418-425. PubMed ID: 28622199 [TBL] [Abstract][Full Text] [Related]
45. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? de Lauretis A; Veeraraghavan S; Renzoni E Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375 [TBL] [Abstract][Full Text] [Related]
46. Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases. Castelino FV; Moua T ACR Open Rheumatol; 2021 May; 3(5):295-304. PubMed ID: 33779080 [TBL] [Abstract][Full Text] [Related]
47. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries. Hilberg O; Hoffmann-Vold AM; Smith V; Bouros D; Kilpeläinen M; Guiot J; Morais A; Clemente S; Daniil Z; Papakosta D; Fretheim H; Neves S; Alfaro TM; Antoniou KM; Valveny N; Asijee G; Soulard S; Wuyts W ERJ Open Res; 2022 Jan; 8(1):. PubMed ID: 35083316 [TBL] [Abstract][Full Text] [Related]
48. Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases. Tanguy J; Pommerolle L; Garrido C; Kolb M; Bonniaud P; Goirand F; Bellaye PS Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502225 [TBL] [Abstract][Full Text] [Related]
49. Characteristics and evaluation of acute exacerbations in chronic interstitial lung diseases. Kershaw CD; Batra K; Torrealba JR; Terada LS Respir Med; 2021 Jul; 183():106400. PubMed ID: 33957435 [TBL] [Abstract][Full Text] [Related]
50. [Epidemiology of fibrosing interstitial lung diseases in the department of Haute Garonne]. Villeneuve T; Prévot G; Lintz F; Mourin G; Ferry G; Bousquet E; Perelroizen H; Boghanim T; Faviez G; Noël-Savina E; Collot S; Le Borgne A; Didier A Rev Mal Respir; 2021 Dec; 38(10):972-979. PubMed ID: 34629221 [TBL] [Abstract][Full Text] [Related]
51. The evolving pharmacotherapy of pulmonary fibrosis. Lota HK; Wells AU Expert Opin Pharmacother; 2013 Jan; 14(1):79-89. PubMed ID: 23265249 [TBL] [Abstract][Full Text] [Related]
57. Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management. Yoo H; Hino T; Hwang J; Franks TJ; Han J; Im Y; Lee HY; Chung MP; Hatabu H; Lee KS Eur J Radiol Open; 2022; 9():100419. PubMed ID: 35445144 [TBL] [Abstract][Full Text] [Related]
58. Progressive pulmonary fibrosis in systemic autoimmune diseases. A real life study. Durán Barata D; Jaureguizar Oriol A; Loarce Martos J; Morell Hita JL; de la Puente Bujidos C; Rigual Bobillo J Reumatol Clin (Engl Ed); 2023 Apr; 19(4):211-214. PubMed ID: 37005131 [TBL] [Abstract][Full Text] [Related]
59. [Interstitial lung diseases among patients hospitalized in the Department of Respiratory Medicine in Radom District Hospital during the years 2000-2009]. Szafrański W Pneumonol Alergol Pol; 2012; 80(6):523-32. PubMed ID: 23109204 [TBL] [Abstract][Full Text] [Related]